Established in 1976, Bedfont® Scientific Ltd. has over 48 years of knowledge and expertise in the design and manufacture of breath analysis medical devices. Its mission is to work with the Bedfont Family and healthcare professionals worldwide to provide cutting-edge breath analysis medical products to the highest standard, through technical innovation and professional business practice.

Working with a global network of over 100 distributors, Bedfont® takes pride in being a forward-thinking, innovative med-tech company. Thanks to constant innovation, it remains a market leader working to fulfil a vision of a world where everyone has access to instant, non-invasive, simple breath testing to aid in medical diagnosis.

Each product range is developed to the highest possible standard at an affordable price, ensuring accessibility worldwide. The devices are non-invasive, easy to use and designed with the patient in mind.

Since 1985, the Smokerlyzer® range has helped people to quit smoking one breath at a time. The gold-standard Micro+™ allows primary care professionals to test patient carbon monoxide (CO) levels to assist in their stop smoking attempt. The Micro+™ also has the ability to test foetal CO levels, so that mums-to-be can also see the effect that smoking has on their unborn child. The piCO™ is suitable for all users, and the piCObaby™ is solely for mums-to-be. All Smokerlyzer® products are equipped with a motivational traffic light system, which means results are easy to interpret. The devices also come with free patient management software, COdata+™.

For over 15 years, the NObreath® FeNO device has been providing accurate analysis of airway inflammation for the control of asthma. Fully portable and with an easy-to-use interface, the NObreath® is also incorporated with antimicrobial technology for optimum infection control. The NObreath® also comes with free patient management software, FeNOchart™. The NObreath® received FDA clearance, conforms to ERS/ATS and joint NICE/BTS/SIGN guidelines.

The Gastrolyzer® range aids in the detection of gastrointestinal disorders and food intolerances. The Gastro+™ tests for hydrogen, whereas the GastroCH4ECK® also tests for methane. Both devices can test for disorders such as lactose, glucose and fructose intolerance, and assist secondary care professionals in testing for IBS and SIBO. The Gastrolyzer® range has been established since 1989.

Located in Harrietsham, Kent, termed the ‘Gateway to Europe’ for being close to major roads, railways and airports, Bedfont’s products are now available across the globe thanks to its network of distributors.

In December 2025, Bedfont® will celebrate 49 years of innovation and its products being available to end users across the globe.